Results: A total of 470 bone metastatic sites were documented among 100 newly diagnosed patients with prostate cancer, aged 51 to 89 (mean age = 68.81, mode = 65, SD = 7.07 years) with a mean prostate-specific antigen (PSA) of 924.32 ng/ml (range = 5.76 to 2223, SD = 2656.47 ng/ml), alkaline phosphatase (ALP), mean = 239.43, range = 45 to 3265, SD = 438.57, digital rectal examination (DRE) risk (median = 3, IQR = 1), International Society of Urological Pathology (ISUP) risk (median = 3, IQR = 1), and D'Amico risk categories (median = 3, IQR = 0). This evidence concerns the gene KLK3 and prostate cancer.